• About
    ▼
    • Overview
    • Leadership
    • Our Team
    • Board of Directors
    • Investors
  • Science
    ▼
    • Overview
    • Highly Cytotoxic T Cells
    • KLRG1
    • Posters & Presentations
  • Pipeline
    ▼
    • Overview
    • ABC008
    • IBM
    • T-LGLL
    • Additional Indications
    • ABC015
  • News
  • Careers
  • Contact
ABCURO

ABCURO

Abcuro

Breakthrough Therapies for Autoimmune Diseases & Cancer

  • About
    • Overview
    • Leadership
    • Our Team
    • Board of Directors
    • Investors
  • Science
    • Overview
    • Highly Cytotoxic T Cells
    • KLRG1
    • Posters & Presentations
  • Pipeline
    • Overview
    • ABC008
    • IBM
    • T-LGLL
    • Additional Indications
    • ABC015
  • News
  • Careers
  • Contact

Dietmar Berger, M.D., Ph.D., Joins Abcuro Therapeutics as Board Observer

June 23, 2022

Newton, Massachusetts, June 23, 2022– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced that Dietmar Berger, M.D., Ph.D., currently the Chief Medical Officer and Head of Global Development at Sanofi will contribute his considerable experience to the company’s Board of

 READ MORE

READ MORE
June 23, 2022
Dietmar Berger, M.D., Ph.D., Joins Abcuro Therapeutics as Board ObserverPress Releases

Abcuro Appoints H. Jeffrey Wilkins, M.D., as Chief Medical Officer

June 21, 2022

Industry veteran brings extensive clinical development experience in immunology, immuno-oncology, and rare diseases to  leadership team Newton, Massachusetts, June 21, 2022– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of H. Jeffrey Wilkins, M.D.,

 READ MORE

READ MORE
June 21, 2022
Abcuro Appoints H. Jeffrey Wilkins, M.D., as Chief Medical OfficerPress Releases

Abcuro Presents Additional Data from Ongoing Phase 1 Clinical Trial of ABC008 in Inclusion Body Myositis (IBM) at GCOM 2022

June 7, 2022

Newton, Massachusetts, June 7, 2022, Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the presentation of additional clinical results from its ongoing Phase 1 clinical trial of its lead product candidate ABC008 in patients with inclusion

 READ MORE

READ MORE
June 7, 2022
Abcuro Presents Additional Data from Ongoing Phase 1 Clinical Trial of ABC008 in Inclusion Body Myositis (IBM) at GCOM 2022Press Releases

Privacy Site Credits Terms of Use

© 2022 Abcuro